Latest News and Press Releases

Newborn screening is the only practical means of diagnosing MLD prior to the onset of symptoms, which is key to achieving optimal outcomes for children and their families with this rapidly progressive...

TOKYO, LONDON and BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd., (TSE: 4151, President and COO: Abdul Mullick, "Kyowa Kirin") and Orchard Therapeutics announced that Japan's...

Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard...

LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical...

LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) --  Orchard Therapeutics, a Kyowa Kirin company, announced it has recently reached an agreement with the Interministerial Commission for...

LONDRES, MADRID y BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, una compañía de Kyowa Kirin, ha anunciado que ha alcanzado recientemente un acuerdo con la Comisión Interministerial...

First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year ...

TOKYO, LONDON and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced presentations from seven abstracts from across its hematopoietic stem cell...

Ten presentations at ESGCT 2024 detail the therapeutic potential and applicability of the company’s platform in rare neurometabolic diseases and beyond Nature manuscript highlights clinical results...

ISTANBUL and LONDON, and BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients...